SCRI Development Innovations, LLC: Multiple Myeloma trials
The registry lists 12 Multiple Myeloma studies with SCRI Development Innovations, LLC as lead sponsor. 3 are open to participants now and 6 have results posted.
Phase 1 2Phase 2 11No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07637578Phase 2
- Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple MyelomaRecruitingNCT06974786Phase 2
- Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaRecruitingNCT05972135Phase 2
- Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02843074Phase 2Results posted
- Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaTerminatedNCT02254551Phase 2Results posted
- Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple MyelomaCompletedNCT02168101Phase 2Results posted
- Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01496118Phase 1/2Results posted
- Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose ChemotherapyCompletedNCT01056276Phase 2Results posted
- Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00536575Phase 1/2Results posted
- SCRI Tissue Testing RegistryTerminatedNCT00965861
- Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple MyelomaCompletedNCT00193557Phase 2
- Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple MyelomaCompletedNCT00193544Phase 2